Glaukos (NYSE:GKOS) Shares Up 3.4%

Shares of Glaukos Co. (NYSE:GKOS - Get Free Report) shot up 3.4% on Friday . The stock traded as high as $98.35 and last traded at $98.35. 105,264 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 666,495 shares. The stock had previously closed at $95.13.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on GKOS. Truist Financial reaffirmed a "buy" rating and set a $110.00 price target on shares of Glaukos in a research note on Monday, April 8th. Stifel Nicolaus reaffirmed a "buy" rating and set a $110.00 price target on shares of Glaukos in a research note on Wednesday, April 3rd. JPMorgan Chase & Co. raised Glaukos from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $66.00 to $91.00 in a research note on Thursday, December 21st. Wells Fargo & Company upped their price target on Glaukos from $83.00 to $103.00 and gave the stock an "overweight" rating in a research note on Thursday, February 22nd. Finally, Mizuho upped their price target on Glaukos from $85.00 to $100.00 and gave the stock a "neutral" rating in a research note on Thursday, April 11th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $99.80.

Glaukos Trading Up 1.3 %

The stock has a market capitalization of $4.84 billion, a PE ratio of -34.68 and a beta of 1.08. The firm has a 50 day moving average price of $91.88 and a 200 day moving average price of $80.73. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.07). The business had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The business's revenue was up 15.7% on a year-over-year basis. During the same period in the prior year, the company earned ($0.53) earnings per share. Equities analysts expect that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Insider Buying and Selling at Glaukos

In other Glaukos news, CFO Alex R. Thurman sold 474 shares of the stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total transaction of $42,835.38. Following the completion of the transaction, the chief financial officer now directly owns 54,916 shares of the company's stock, valued at $4,962,758.92. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CFO Alex R. Thurman sold 434 shares of the firm's stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the transaction, the chief financial officer now directly owns 54,166 shares of the company's stock, valued at $5,163,644.78. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Alex R. Thurman sold 474 shares of the firm's stock in a transaction on Tuesday, April 2nd. The stock was sold at an average price of $90.37, for a total value of $42,835.38. Following the completion of the transaction, the chief financial officer now directly owns 54,916 shares of the company's stock, valued at $4,962,758.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 242,881 shares of company stock valued at $22,906,633. Company insiders own 7.80% of the company's stock.

Institutional Investors Weigh In On Glaukos

A number of institutional investors and hedge funds have recently made changes to their positions in GKOS. National Bank of Canada FI purchased a new stake in shares of Glaukos in the fourth quarter worth $46,000. GAMMA Investing LLC purchased a new stake in Glaukos during the fourth quarter valued at about $55,000. Tower Research Capital LLC TRC raised its position in Glaukos by 257.8% during the first quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier's stock valued at $62,000 after purchasing an additional 892 shares in the last quarter. Quadrant Capital Group LLC raised its position in Glaukos by 54.8% during the fourth quarter. Quadrant Capital Group LLC now owns 929 shares of the medical instruments supplier's stock valued at $74,000 after purchasing an additional 329 shares in the last quarter. Finally, Captrust Financial Advisors raised its position in Glaukos by 17.1% during the second quarter. Captrust Financial Advisors now owns 1,738 shares of the medical instruments supplier's stock valued at $79,000 after purchasing an additional 254 shares in the last quarter. Hedge funds and other institutional investors own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.